Filing Flows › Travere Therapeutics (TVTX) › Q3 2026 › vs Q3 2025
Travere Therapeutics (TVTX) Q3 2026 vs Q3 2025 (year over year)
Travere Therapeutics's revenue rose $59.7M (+36%) from $165M in Q3 2025 to $225M in Q3 2026. The biggest changes: Total net product sales +$107M (+95%); License and collaboration revenue −$47.3M (-92%).
Travere Therapeutics, Q3 2026: revenue $225M (+36% year over year), operating margin -30.3%, net loss $52.3M, operating cash flow $98.2M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| FILSPARI | $200M | $90.9M | $109M | +120% |
| Tiopronin products | $20.0M | $22.2M | −$2.2M | -10% |
| Total net product sales | $220M | $113M | $107M | +95% |
| License and collaboration revenue | $4.4M | $51.7M | −$47.3M | -92% |
| Revenue | $225M | $165M | $59.7M | +36% |
| Other income, net | $9.9M | $783K | $9.1M | 13× |
| Income tax benefit | $5.9M | −$8K | $5.9M | — |
| Net loss | $52.3M | −$25.7M | $78.0M | — |
| Costs & expenses | $293M | $166M | $127M | +77% |
| Operating costs | $293M | $140M | $153M | +109% |
| Cost of revenue | $2.9M | $1.6M | $1.3M | +81% |
| Research & development | $70.3M | $51.9M | $18.4M | +35% |
| SG&A | $98.4M | $71.0M | $27.4M | +39% |
| Other operating costs | $121M | $15.4M | $106M | +686% |
| Operating cash sources | $151M | −$11.4M | $162M | — |
| Depreciation & amortization | $5.2M | $15.8M | −$10.6M | -67% |
| Share-based compensation | $23.4M | $11.3M | $12.2M | +108% |
| Working capital & other | $122M | −$38.4M | $160M | — |
| Net loss absorbed | $52.3M | −$25.7M | $78.0M | — |
| Operating cash flow | $98.2M | $14.3M | $83.9M | +586% |
Questions
How much did Travere Therapeutics's revenue grow year over year in Q3 2026?
Travere Therapeutics's revenue rose $59.7M (+36%) from $165M in Q3 2025 to $225M in Q3 2026.
What drove Travere Therapeutics's revenue change in Q3 2026?
Total net product sales +$107M (+95%); License and collaboration revenue −$47.3M (-92%).